B. Pugin et al. / Tetrahedron: Asymmetry 17 (2006) 544–549
549
ent (flow rate 1 ml/min) from 0% to 85% solvent B with-
in 28 min and UV detection at 280 nm. To protect tetra-
hydrofolic acid from oxidative degradation, all eluents
were continuously flushed with argon.
7. Uwajima, T.; Oshiro, T.; Eguchi, T.; Kuge, Y.; Horiguchi,
A.; Igarashi, A.; Mochida, M.; Iwakura, K. Biochem.
Biophys. Res. Commun. 1990, 171, 684–689.
8
. M u¨ ller, H. R.; Ulmann, M.; Conti, J.; M u¨ rdel, G. EP
495204, 1991 (assigned to Eprova AG).
0
9
. For a recent overview see: Blaser, H. U.; Malan, Ch.;
Pugin, B.; Spindler, F.; Steiner, H.; Studer, M. Adv. Synth.
Catal. 2003, 345, 103–151.
The diastereoisomers of tetrahydrofolic acid were
determined by using the following HPLC method.
The eluent was prepared by mixing 960 ml water,
8
1
0. Boyle, P. H.; Keating, M. T. J. Chem. Soc., Chem.
Commun. 1974, 375–376.
4
0 ml acetonitrile, 8 g b-cyclodextrine, and 10 ml tri-
ethylamine. By adding of acetic acid, the pH was
adjusted to pH 7.0 at which point 274 ll 37%
formaldehyde was added. A solution of tetrahydrofolic
acid in the eluent (0.5 mg/ml) was analyzed (flow rate
11. (a) M u¨ ller, H. R.; Moser, R.; Groehn, V.; Pugin, B. WO
01/04120, 2001 (assigned to Eprova AG); (b) Groehn, V.;
Moser, R.; Pugin, B. Adv. Synth. Catal. 2005, 347, 1855–
1
862.
2. (a) Brunner, H.; Huber, C. Chem. Ber. 1992, 125, 2085–
093; (b) Brunner, H.; Bublak, P.; Helget, M. Chem. Ber./
1
1
ml/min) on an ODS column (Macherey and Nagel
2
Nucleosil/CART, 120-5, 250 · 4 mm) with UV-detec-
tion at 280 nm.
Recl. 1997, 130, 55–61; (c) Brunner, H.; Rosenboem, S.
Monatsh. Chem. 2000, 131, 1371–1382.
1
1
3. Sinou, D. Adv. Synth. Catal. 2002, 344, 221–237.
4. Pugin, B.; Landert, H.; Spindler, F.; Blaser, H. U. Adv.
Synth. Catal. 2002, 344, 974–979; Pugin, B. Chimia 2001,
References
5
5, 719–724.
5. Malmstr o¨ m, T.; Andersson, C. Chem. Commun. 1996,
135–1136; Malmstr o¨ m, T.; Andersson, C. J. Mol. Catal.
1
1
. Bailey, L. B. In Folates in Health and Disease; Bailey, L.
B., Ed.; Marcel Dekker: New York, Basel, Hong Kong,
995; Vol. 1, pp 23–42; Groehn, V.; Moser, R. Pteridines
999, 10, 95–100.
. Mini, E.; Trave, F.; Rustum, Y. M.; Bertino, J. R.
Pharmacol. Ther. 1990, 47, 1–19.
. Perna, F.; De Santo, N. G.; Ingrosso, D. Miner. Electro-
lyte Metab. 1997, 23, 174–178.
. Nygard, O.; Nordrehaug, J. E.; Refsum, H.; Ueland, P.
M.; Farstad, M.; Vollset, S. E. Engl. J. Med. 1997, 337,
1
A: Chem. 1999, 139, 259–270.
1
1
1
1
6. Pugin, B. Patent WO 0104131 A1, 2001 (assigned to
Solvias AG).
7. Pugin, B.; Landert, H. Patent WO 9801457 A1, 1998
2
3
4
(
assigned to Novartis AG); Koellner, C.; Pugin, B.; Togni,
A. J. Am. Chem. Soc. 1998, 120, 10274–10275.
8. Pugin, B.; Steiner, I.; Aufdenblatten, R. N.; Togni, A.
Patent EP 1002801 A1, 2000 (assigned to Solvias AG).
9. Spindler, F.; Blaser, H. U. In Transition Metals for
Organic Synthesis, 2nd ed.; Bolm, C., Beller, M., Eds.;
Wiley-VCH: Weinheim, 2004; Vol. 2, pp 113–123.
0. Nagel, U.; Kinzel, E.; Andrade, J.; Prescher, G. Chem.
Ber. 1986, 119, 3326–3343.
1
1
2
30–236.
5
. (a) Temple, C.; Elliott, R. D.; Rose, J. D.; Montgomery, J.
A. J. Med. Chem. 1979, 22, 731–734; (b) Blair, J. A.;
Saunders, K. J. Anal. Biochem. 1970, 34, 376–381.
. Blakley, R. L. Biochemistry 1957, 65, 331–348.
2
6